In the last ten years, the value of the Indian bio-economy has grown significantly. As a result, India is now ranked third in Asia Pacific and among the top 12 global biotechnology destinations. According to a forecast by Investinindia, the country's biotechnology market would reach $80.12 billion in 2022, up 14% from the previous year, thanks mainly to COVID-19, which has given the sector a much-needed boost. India is positioned to become one of the top locations for bioinnovation and biomanufacturing in the near future.
A key element in the growth of the biotech startup ecosystem is India's developing entrepreneurial culture. More and more young entrepreneurs in the nation are eager to discover the potential of the biotech industry. Numerous businesspeople have ground-breaking concepts that can revolutionise healthcare, agriculture, and the environment.
India Pharma Outlook has identified the top 10 startups in this area who have demonstrated a relentless pursuit of excellence. These startups are blazing a trail for others to follow and setting an example by demonstrating their commitment to meeting customer expectations and advancing the market through their inventive nature. One such organization is Mestastop Solutions, a cutting-edge company delving deeply into metastasis research to build and develop platforms to determine a patient's risk of developing metastasis and identify cutting-edge intervention ways to prevent metastasis.The organization's mission is to become 'the metastasis specialists' by building a top-notch metastasis-focused R&D facility and analysing the intricate biology of metastasis for the first time. Mestastop specialises in discovering the critical rate-limiting vital processes in the as-yet-unexplored field of metastatic biology.
Mestastop has established three patented (filed) systems, both in vitro and in vivo, together with patient tumour translational validation, to comprehend the complexity of metastatic drug discovery and early prognostic diagnosis. These platforms are ready to be used for drug development, drug repurposing, and profiling of current anti-cancer leads or candidates for their ability to prevent metastasis. The business is focused on research and development with the goal of assisting the biotech and pharmaceutical industries in analysing the biology of cancer metastasis beneficial for early predictive metastasis diagnostics and medication discovery.
'We are learning from the patients and moving from the bedside to the bench to reduce the likelihood of failure because our platform is verified using patient sample data. Our retrospective clinical trial has shown that our platforms can select the best drugs. We have combined machine learning algorithms with biological data gathered from patients to forecast the likelihood of metastasis in patients with primary tumours. The continuing prospective clinical trial on this is quite positive'. The company's founding director, Dr Arnab Roy Chowdhury, adds, 'Lastly, we have developed innovative animal models that can measure metastasis in just six weeks with 100 per cent accuracy, which is a game-changer.
Additionally, the business created a subsidiary in the US and plans to do the same in Europe very soon. The company's future efforts will be concentrated on conducting additional studies and clinical trials aimed at postponing and preventing metastasis, which will ultimately help it realise its business objectives. These studies would be the first successful attempt to target metastatic biology and aim to postpone metastasis in neo-adjuvant or adjuvant situations.